ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
RPG Life Sciences announced a strategic reorganization of its API business into a new subsidiary, RPGAP, involving a PE partnership and two bolt-on acquisitions to drive growth.
RPG Life Sciences reported robust Q1 FY27 results with 15.8% revenue growth and 17.0% PAT growth. Strategy focuses on building a specialty/chronic portfolio and expanding API and international footprint.
RPG Life Sciences reports 8.3% YoY revenue growth to ₹707.5 cr in FY26, driven by domestic formulations outperforming the market by 1.6x.
RPG Life Sciences delivered strong Q4 FY26 performance with 23.6% revenue growth and 58.1% PAT growth (excl. exceptions), driven by Domestic Formulations and margin expansion.